UK consults on value based pricing system
This article was originally published in Scrip
The UK department of health today released for consultation its plans for introducing a value-based pricing system to determine how much it will pay for new medicines. The plan focuses on determining maximum prices or thresholds for medicines, which will reflect the different values that different treatments offer. The proposals also touch on the role that NICE, the National Institute for health and Clinical Excellence, will play.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.